UnitedHealthcare (UHC), the second-largest U.S. commercial insurance provider, issued a positive medical policy for Lumbar Total Disc Replacement (TDR).
UHC covers over 16 million patients; now three of the four largest U.S. commercial providers have positive coverage for Centinel Spine’s prodisc® L anterior lumbar total disc. A recent policy change by TRICARE, the Military Health System, added 9.5 million covered lives; combined, these decisions give >25 million additional patients access to prodisc L.
Over 400 publications have demonstrated long-term effectiveness in >125,000 prodisc patients during 30+ years of clinical evidence generated by Centinel Spine and its originators.
The Viscogliosi Bros. purchased prodisc-L from Aesculap in 1999 and spun it into a standalone company, Spine Solutions, which commercialized prodisc-C and commenced U.S. clinical trials. Synthes purchased Spine Solutions in 2Q03. In 2017, Centinel Spine acquired worldwide prodisc TDR assets from DePuy Synthes Products.
UnitedHealthcare (UHC), the second-largest U.S. commercial insurance provider, issued a positive medical policy for Lumbar Total Disc Replacement (TDR).
UHC covers over 16 million patients; now three of the four largest U.S. commercial providers have positive coverage for Centinel Spine's prodisc® L anterior lumbar total disc. A recent...
UnitedHealthcare (UHC), the second-largest U.S. commercial insurance provider, issued a positive medical policy for Lumbar Total Disc Replacement (TDR).
UHC covers over 16 million patients; now three of the four largest U.S. commercial providers have positive coverage for Centinel Spine’s prodisc® L anterior lumbar total disc. A recent policy change by TRICARE, the Military Health System, added 9.5 million covered lives; combined, these decisions give >25 million additional patients access to prodisc L.
Over 400 publications have demonstrated long-term effectiveness in >125,000 prodisc patients during 30+ years of clinical evidence generated by Centinel Spine and its originators.
The Viscogliosi Bros. purchased prodisc-L from Aesculap in 1999 and spun it into a standalone company, Spine Solutions, which commercialized prodisc-C and commenced U.S. clinical trials. Synthes purchased Spine Solutions in 2Q03. In 2017, Centinel Spine acquired worldwide prodisc TDR assets from DePuy Synthes Products.
Copy to clipboard 
